RxDoctor Payments Data

Holly Young

Acute Care · Seward, NENPI 1306164942

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Collegium Pharmaceutical, Inc. at 41.0% of the total. 2025 is the largest year on record at $377, more than ten times the $25 reported in 2021.

$638in general payments, 2019–2025

Across 28 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$262
  • Vertex$228
  • Pfizer$48
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$47
  • Biodelivery Sciences International, Inc.$25
  • Conetic Solutions, Inc.$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$638 in reported general payments places this provider in the 65th percentile of 103 acute care providers in Nebraska.

See all acute care providers in Nebraska

Medicare billing

Part B allowed, 2024
$59,583
Medicare patients
224
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl201$172,509
Xtampza ErOxycodone Myristate299$157,192
Nurtec OdtRimegepant Sulfate37$45,429
RelistorMethylnaltrexone Bromide18$40,756
Buprenorphine116$34,974
BotoxOnabotulinumtoxina19$24,395
Nucynta ErTapentadol Hcl45$18,826
SymproicNaldemedine Tosylate26$13,601
NucyntaTapentadol Hcl23$12,247
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl55$11,193
ButransBuprenorphine20$10,226
LinzessLinaclotide15$10,196
Buprenorphine Hcl313$9,520
Pregabalin219$7,987
SavellaMilnacipran Hcl13$6,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er, Nucynta$262$360,774568 claims
PfizerNurtec Odt$48$45,42937 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$47$40,75618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 103 acute care providers in Nebraska.

Other acute care in Seward

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →